May 28, 2025 03:53PM Clear Street Reiterates Buy Rating on Y-mAbs Therapeutics (YMAB) Following Positive Radiopharma R&D Update

May 19, 2025 06:46AM Y-mAbs Therapeutics (YMAB) PT Lowered to $11 at H.C. Wainwright

May 7, 2025 07:05AM Y-mAbs Therapeutics (YMAB) Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines

Apr 25, 2025 07:35AM Y-mAbs Therapeutics (YMAB) Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in R/R NHL

Apr 22, 2025 06:16AM BofA Securities Downgrades Y-mAbs Therapeutics (YMAB) to Underperform

Mar 5, 2025 09:14AM Y-mAbs Therapeutics (YMAB) PT Lowered to $18 at Jones Trading

Mar 4, 2025 04:37PM Y-mAbs Therapeutics (YMAB) PT Lowered to $7 at Morgan Stanley

Mar 4, 2025 12:56PM Y-mAbs Therapeutics (YMAB) PT Lowered to $19 at Cantor Fitzgerald

Mar 4, 2025 12:54PM Y-mAbs Therapeutics (YMAB) PT Lowered to $12 at BofA Securities

Mar 4, 2025 10:16AM Y-mAbs Therapeutics (YMAB) PT Lowered to $18 at Clear Street

Mar 3, 2025 07:30AM Y-mAbs Therapeutics (YMAB) Announces Publication of Phase 2 Interim Results

Jan 15, 2025 11:09AM Oppenheimer Reiterates Outperform Rating on Y-mAbs Therapeutics (YMAB)

Jan 10, 2025 07:10AM Y-mAbs Therapeutics (YMAB) Provides Strategic Business Update and 2025 Priorities

Dec 12, 2024 04:39PM Clear Street Starts Y-mAbs Therapeutics (YMAB) at Buy

Nov 11, 2024 08:27AM Y-mAbs Therapeutics (YMAB) PT Lowered to $24 at BMO Capital

Nov 8, 2024 06:38AM Y-mAbs Therapeutics (YMAB) Misses Q3 EPS by 1c, provides guidance

Nov 4, 2024 07:38AM Y-mAbs Therapeutics (YMAB) and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA in Japan

Sep 6, 2024 10:16AM BMO Capital Reiterates Outperform Rating on Y-mAbs Therapeutics (YMAB)

Sep 6, 2024 07:30AM Y-mAbs Therapeutics (YMAB) Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform

Aug 16, 2024 06:05AM Cantor Fitzgerald Starts Y-mAbs Therapeutics (YMAB) at Overweight

Aug 12, 2024 04:08PM Y-mAbs Therapeutics (YMAB) PT Lowered to $25 at BMO Capital

Aug 12, 2024 06:33AM Y-mAbs Therapeutics (YMAB) Misses Q2 EPS by 9c ; Offers Guidance

Jul 11, 2024 04:04PM Jones Trading Starts Y-mAbs Therapeutics (YMAB) at Buy

Jul 1, 2024 04:06PM Y-mAbs Therapeutics (YMAB) Appoints Peter Pfreundschuh as CEO

Jun 28, 2024 06:02AM Truist Securities Starts Y-mAbs Therapeutics (YMAB) at Buy